Ribomic has announced positive top-line results from its Phase I/IIa single ascending dose SUSHI study of RBM-007 in patients with wet Age-Related Macular Degeneration (wet AMD).

The open-label, dose escalation SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favour of the anti-FGF2 aptamer.

Nine subjects who had received ≥3 anti-VEGF treatments earlier without resolution of wet AMD participated in the study.

They received a single intravitreal injection of RBM-007 in three sequential dose cohorts.

Ribomic recruited patients who had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy.

Secondary outcomes at the primary study endpoint of 28 days showed evidence of bioactivity of RBM-007.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A single intravitreal injection of RBM-007 in the study eye was well-tolerated and indicated bioactivity in a majority of subjects with wet AMD.

The company is planning for the next multi-dose Phase II clinical trial, which is underway, with enrolment expected to start in the third quarter of 2019.

Ribomic CEO and president Yoshikazu Nakamura said: “We are very encouraged by the results of SUSHI study. This was designed as a first-in-human, single-dose safety study and has exceeded our expectations from the standpoint of bioactivity.

“We will promote the clinical development of RBM-007 to provide wet AMD patients with this new solution as quickly as possible.”

Wet AMD is caused by the formation of abnormal and leaky new blood vessels under the retina and is the leading cause of blindness in the US and Europe.